{"filing":{"accession_number":"0001171843-26-005759","cik":"0001505065","ticker":"BRSYF","company_name":"Brainsway Ltd.","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"f6k_082626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505065/000117184326005759/f6k_082626.htm"},"events":[{"id":29902,"run_id":27399,"accession_number":"0001171843-26-005759","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces publication of peer-reviewed clinical data demonstrating a 70% reduction in suicidal ideation among MDD patients treated with BrainsWay's Deep TMS technology. While the data supports the company's product efficacy and competitive positioning, it is a secondary analysis of previously published trial data (not a new FDA approval or regulatory milestone). The disclosure is material to investors as it strengthens the clinical evidence base for the company's lead product and supports market positioning, but it does not fit the specific event categories of earnings release, M\u0026A, regulatory approval, or other defined types—making it an operational/strategic disclosure about product clinical validation.","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":[{"id":32331,"accession_number":"0001171843-26-005759","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces publication of peer-reviewed clinical data demonstrating a 70% reduction in suicidal ideation among MDD patients treated with BrainsWay's Deep TMS technology. While the data supports the company's product efficacy and competitive positioning, it is a secondary analysis of previously published trial data (not a new FDA approval or regulatory milestone). The disclosure is material to investors as it strengthens the clinical evidence base for the company's lead product and supports market positioning, but it does not fit the specific event categories of earnings release, M\u0026A, regulatory approval, or other defined types—making it an operational/strategic disclosure about product clinical validation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T11:31:38.523457+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32331,"accession_number":"0001171843-26-005759","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces publication of peer-reviewed clinical data demonstrating a 70% reduction in suicidal ideation among MDD patients treated with BrainsWay's Deep TMS technology. While the data supports the company's product efficacy and competitive positioning, it is a secondary analysis of previously published trial data (not a new FDA approval or regulatory milestone). The disclosure is material to investors as it strengthens the clinical evidence base for the company's lead product and supports market positioning, but it does not fit the specific event categories of earnings release, M\u0026A, regulatory approval, or other defined types—making it an operational/strategic disclosure about product clinical validation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T11:31:38.523457+00:00","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-08-27"}]}